Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre-Reference-Cited by-同舟云学术

Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre

Published:2022-09-09 Issue:4 Volume:37 Page:779-784
ISSN:0950-222X
Container-title:Eye
language:en
Short-container-title:Eye

Author:

Fu Dun Jack^ORCID,Hanumunthadu Daren,Keenan Tiarnan D. L.^ORCID,Wagner Siegfried,Balsakas Konstantinos,Keane Pearse A.^ORCID,Patel Praveen J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://www.nature.com/articles/s41433-022-02220-1.pdf

Reference21 articles.

1. McKibbin M, Devonport H, Gale R, Gavin M, Lotery A, Mahmood S, et al. Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye. 2015;29 Suppl 1:S1–11. https://doi.org/10.1038/eye.2015.77.

2. Hsu J, Regillo CD. Poorer outcomes in real-world studies of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Ophthalmology. 2020;127:1189–90. https://doi.org/10.1016/j.ophtha.2020.03.034.

3. Almuhtaseb H, Johnston RL, Talks JS, Lotery AJ. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group. Eye. 2017;31:1582–8. https://doi.org/10.1038/eye.2017.108.

4. Little K, Ma JH, Yang N, Chen M, Xu H. Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283–91. https://doi.org/10.1016/j.ebiom.2018.11.029.

5. Okeagu CU, Agrón E, Vitale S, Domalpally A, Chew EY, Keenan TDL. Principal cause of poor visual acuity after neovascular age-related macular degeneration: age-related eye disease study 2 report number 23. Ophthalmol Retin. 2021;5:23–31. https://doi.org/10.1016/j.oret.2020.09.025.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The environmental impact of treating macular disease;Eye;2023-03-10